News and Events - Catalent
WEBFeb 2, 2024 · Catalent Appoints David McErlane as Biologics Segment Leader. Sep 18, 2023. Mr. McErlane will lead all of Catalent’s Biologics businesses and global service offerings – including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services.
Novo Holdings to Acquire Catalent
WEBFeb 5, 2024 · Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to this announcement, and a 47.5% premium to the 60-day volume-weighted average price …
Moderna and Catalent Partner on COVID-19 Vaccine Candidate
WEBJun 25, 2020 · Moderna and Catalent today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.
Catalent to Acquire Metrics Contract Services for $475 Million
WEBAug 9, 2022 · Upon completion, the acquisition will strengthen Catalent’s capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs, while also expanding Catalent’s capacity to handle highly potent compounds.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
WEBJan 5, 2023 · Catalent & Sarepta partner to manufacture delandistrogene moxeparvovec, an advanced candidate to treat Duchenne muscular dystrophy.
Catalent Acquires Princeton Cell Therapy Facility from Erytech
WEBApr 25, 2022 · Catalent's agreement with Erytech Pharma acquires the state-of-the-art cell therapy manufacturing facility in Princeton for $44.5 million.
Catalent Opens Therapy Manufacturing Facilities in Belgium
WEBDec 8, 2022 · The newly completed facility is the latest addition to Catalent’s Gosselies campus, which already includes a 67,000-square-foot (6,200-square-meter) clinical manufacturing facility offering customers advanced …
Catalent Announces New Operating Structure
WEBJul 5, 2022 · Catalent's new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
News Details - Catalent
WEBAug 29, 2023 · SOMERSET, N.J.-- (BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better biopharmaceutical treatments for patients worldwide, today announced several initiatives reflecting its ongoing commitment to strong corporate governance and shareholder value creation.
Catalent Stockholders Approve Transaction with Novo Holdings
WEBMay 29, 2024 · Based on the preliminary count of the voting results from today’s Special Meeting, Catalent stockholders voted to approve the transaction with 99.2% of ballots cast in favor of the proposed transaction.